<DOC>
	<DOCNO>NCT00900627</DOCNO>
	<brief_summary>The main purpose study determine AZD8931 improve efficacy standard chemotherapy treatment advance breast cancer . This study conduct 2 part : first part ( phase I ) determine dose AZD8931 safely administer paclitaxel chemotherapy . The second part ( phase II ) determine efficacy safety AZD8931 combination paclitaxel chemotherapy breast cancer .</brief_summary>
	<brief_title>Phase I/II AZD8931/Paclitaxel Treatment Advanced Solid Tumours ( Phase I ) Advanced Breast Cancer ( Phase II )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Male/ female solid , malignant tumour unresponsive standard therapy ( Phase I ) . Female patient advance breast cancer low HER2 expression ( Phase II ) Suitable paclitaxel chemotherapy Life expectancy 12 week Inadequate kidney , liver , heart , gastric , lung eye function Hypersensitive paclitaxel No symptomatic uncontrolled brain metastasis Previous taxane chemotherapy within 12 month ( Phase II )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumour</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Secondary</keyword>
</DOC>